NEWS & EVENTS

Latest news and upcoming events

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
01 Jul 2026

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Upcoming events

  • Swiss Biotech Day 2026
    4 May - 5 May, 2026
    Zurich

    download

  • Goodwin’s European Summit: 2026 Emerging VC Leaders in Life Sciences
    20 -22 May, 2026
    Malta

    download

  • CFO Forum
    21 - 22 May, 2026
    Málaga

    download

  • BIOSPAIN
    29 September - 1 October, 2026
    Bilbao

    download
AM-Pharma and Kyowa Kirin Sign Exclusive License Agreement for Commercialization of Ilofotase Alfa in Japan<
08 Sep 2021

AM-Pharma and Kyowa Kirin Sign Exclusive License Agreement for Commercialization of Ilofotase Alfa in Japan

Overall deal value is up to EUR 245 million.
VTX‐801 Receives U.S. FDA Fast Track Designation for the Treatment of Wilson Disease<
13 Aug 2021

VTX‐801 Receives U.S. FDA Fast Track Designation for the Treatment of Wilson Disease

Compelling additional preclinical data further support therapeutic potential of gene therapy product to treat PFIC3.
LAVA Therapeutics Announces Treatment of First Patient in Phase 1/2a Clinical Trial of LAVA-051 for Multiple Hematological Malignancies<
13 Jul 2021

LAVA Therapeutics Announces Treatment of First Patient in Phase 1/2a Clinical Trial of LAVA-051 for Multiple Hematological Malignancies

LAVA’s first-in-class gamma-delta bsTCE to be evaluated as a treatment for chronic lymphocytic leukemia, multiple myeloma and acute myeloid leukemia.
Xeltis initiates first-ever pivotal trial of a synthetic restorative pulmonary heart valve<
08 Jul 2021

Xeltis initiates first-ever pivotal trial of a synthetic restorative pulmonary heart valve

Patient’s own tissue naturally turn device into living heart valves and may reduce need for re-interventions
Adcendo Appoints Michael Pehl as Chief Executive Officer<
07 Jul 2021

Adcendo Appoints Michael Pehl as Chief Executive Officer

Experienced Industry Leader with successful Oncology, Immunotherapy & ADC Development Track Record
AM-Pharma Appoints Mark Altmeyer as Chairman of its Supervisory Board<
06 Jul 2021

AM-Pharma Appoints Mark Altmeyer as Chairman of its Supervisory Board

Mr. Altmeyer will provide important guidance as the Company expands its global clinical development program.
Ysios Capital’s portfolio company CVRx Inc. prices IPO on NASDAQ<
05 Jul 2021

Ysios Capital’s portfolio company CVRx Inc. prices IPO on NASDAQ

This is a major achievement for Ysios as CVRx is its fifth portfolio company to be listed on NASDAQ, and the second within just three months.
AM-Pharma Enrolls First Patient in Japan for Ongoing Phase III SA-AKI Pivotal REVIVAL Trial<
01 Jul 2021

AM-Pharma Enrolls First Patient in Japan for Ongoing Phase III SA-AKI Pivotal REVIVAL Trial

REVIVAL study is evaluating ilofotase alfa, the Company’s proprietary recombinant human alkaline phosphatase, for the treatment of sepsis-associated acute kidney injury (SA-AKI).
Aura Biosciences Assembles New Bladder Cancer Focused Scientific Advisory Board<
18 Jun 2021

Aura Biosciences Assembles New Bladder Cancer Focused Scientific Advisory Board

The new SAB will be comprised of seven members and will work closely with Aura’s senior management.
AM-Pharma Appoints Martijn Negen as VP Commercial Strategy<
16 Jun 2021

AM-Pharma Appoints Martijn Negen as VP Commercial Strategy

Martijn Negen has over 20 years of experience in pharmaceutical, biotech and diagnostic companies.

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.